Table I.

Treatment initiation¹ with an ACE inhibitor or an angiotensin-II receptor antagonist by lifestyle and health characteristics among 226 people with screen-detected type 2 diabetes in 54 general practices in Denmark 2001–2006.

	All			Treatment initiation (410 days)
Characteristics	No.	%2	CIP3 (95% CI)	CIP difference (95% CI)
At baseline
Smoking
Lifetime non-smoker	69	30.8	0.48 (0.37–0.60)	Ref
Stopped smoking	79	35.3	0.43 (0.33–0.55)	–0.05 (–0.21–0.11)
Current smoker	76	33.9	0.60 (0.47–0.73)	0.12 (–0.06–0.29)
BMI (kg/m2)
< 25	25	11.1	0.44 (0.27–0.66)	Ref
25–29	89	39.4	0.46 (0.36–0.57)	0.02 (–0.21–0.24)
≥ 30	112	49.6	0.56 (0.45–0.66)	0.11 (–0.11–0.34)
Self-rated health(SF36)
≤ 25 percentile(52)	50	22.9	0.58 (0.45–0.72)	0.04 (–0.13–0.22)
25–75 percentile	114	52.3	0.54 (0.44–0.65)	Ref
≥ 75 percentile(87)	54	24.8	0.40 (0.28–0.54)	–0.14 (–0.31–0.03)
Mental
≤ 25 percentile(76)	57	26.0	0.58 (0.45–0.72)	0.09 (–0.10–0.28)
25–75 percentile	68	31.1	0.49 (0.37–0.63)	Ref
≥ 75 percentile(92)	94	42.9	0.47 (0.38–0.58)	–0.02 (–0.19–0.15)
Total cholesterol(mmol/l)
< 5	61	27.9	0.49 (0.37–0.63)	Ref
5–5.9	76	34.7	0.46 (0.36–0.58)	–0.03 (–0.21–0.15)
6–6.9	51	23.3	0.53 (0.39–0.67)	0.04 (–0.16–0.23)
7–	31	14.2	0.64 (0.42–0.86)	0.15 (–0.12–0.43)
HbA1c (%)
< 6	47	20.8	0.49 (0.36–0.65)	Ref
6–6.9	108	47.8	0.53 (0.43–0.63)	0.03 (–0.15–0.21)
7–7.9	36	15.9	0.44 (0.30–0.62)	–0.05 (–0.27–0.17)
8–	35	14.5	0.54 (0.34–0.76)	0.04 (–0.22–0.31)
Blood pressure (mmHg)
Systolic
< 140	81	35.8	0.36 (0.26–0.49)	Ref
≥ 140–159	81	35.8	0.49 (0.38–0.60)	0.12 (–0.04–0.28)
≥ 160–	64	28.3	0.72 (0.58–0.85)	0.36 (0.17–0.54)
Diastolic
< 90	138	61.1	0.40 (0.32–0.49)	Ref
≥ 90	88	38.4	0.66 (0.55–0.76)	0.25 (0.11–0.39)

¹410 days after exceeded thresholds. ²of completed information. Missing data 5%. ³cumulative initiation proportion.